UCB (OTCMKTS:UCBJY) Sets New 1-Year High – What’s Next?

UCB SA (OTCMKTS:UCBJY)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $156.07 and last traded at $155.70, with a volume of 1207 shares trading hands. The stock had previously closed at $152.0250.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on UCBJY shares. Zacks Research downgraded shares of UCB from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a research note on Sunday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy”.

UCB Stock Up 0.5%

The stock’s 50 day moving average price is $143.07 and its two-hundred day moving average price is $130.30.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.